Breast Cancer

Breast Cancer
No. Study TitlePrinciple Investigator SponsorTypeRecruitingStudy status
1APPALACHES study: A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer.Dr. Hikmat Abdel-RazeqEORTCClinical TrialYesOngoing
2ICRG 1021 study: Multicentre, International neoadjuvant randomized double-blind trial comparing Fulvestrant® to a combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in patients with operable luminal breast cancer responding to Fulvestrant.Dr. Hikmat Abdel-RazeqICRGClinical TrialYesOngoing
3AMALEE (Ribo 400/600) study: A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease.Dr. Hikmat Abdel-RazeqNovartisClinical TrialYesOngoing
4Right Choice study: A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor- positive/HER2-negative inoperable locally advanced or metastatic breast cancer.Dr. Hikmat Abdel-RazeqNovartisClinical TrialYesOngoing
5PhranceSCa study: A randomized, multicenter, open-label Cross-over study to evaluate patient Preference and satisfaction of Subcutaneous administration of the Fixed-dose combination of pertuzumab And trastuzumab in patients with HER2positive Early Breast Cancer.Dr. Hikmat Abdel-RazeqRocheClinical TrialNoOngoing
6MONALEESA-3 Study: A randomized double-blind, placebo controlled Study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment.Dr. Hikmat Abdel-RazeqNovartisClinical TrialNoOngoing
7COMPLEEMENT-1 study: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib  (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone  receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease.Dr. Hikmat Abdel-RazeqNovartisClinical TrialNoOngoing
8TRIPOLI study: Triple Negative Breast Cancer Prospective Registry in Middle East and Africa.Dr. Hikmat Abdel-RazeqMerckRegistry StudyNoOngoing
9PIK3CA Registry - A descriptive study of PIK3CA mutations in patients with HR+/Her2- advanced breast cancer.Dr. Hikmat Abdel-RazeqNovartisRegistry StudyPending  Ongoing
10A tattoo or a clip? A study to compare between applying a tattoo or a clip to axillary lymph nodes in breast cancer patients who undergo SLNBx. A prospective, double blind and randomized pilot study.Dr. Mahmoud Al-MasriKHCCClinical TrialNoOn-going